

were positive for JE IgM and therefore considered to be JE case-patients. JE incidence per 100,000 persons in the district declined from 2.3 cases in 2010 to 0.81 in 2011 to 0.58 in 2012 (Figure). The decline in JE incidence since 2010 could be a consequence of JE vaccination activities in Kushinagar. In 2010, a mass vaccination campaign with 1 dose of JE vaccine (SA 14–14–2 strain) was conducted among children 1–15 years of age. Subsequently, the vaccine was introduced into the childhood vaccination program as a 1-dose strategy in 2011 and a 2-dose strategy in 2013. Unfortunately, information about evaluated coverage of JE vaccine is not available from the district. On the other hand, the average annual incidence of JE-negative AES during the same period was 16 cases per 100,000 persons (95% CI 14.8–17.2), and this incidence has remained relatively stable since 2008.

With the isolation of enteroviruses from JE-negative AES patients, waterborne transmission has been hypothesized, and the focus of intervention has shifted toward improving sanitation and water quality. However, enteroviruses were detected only in

a small proportion of AES patients. Although the quality of AES surveillance needs to be improved, as Kakkar et al. suggested (1), further studies are needed to understand the etiology of JE-negative AES in the district and the risk factors for transmission. These studies might include systematically investigating patients and environmental samples for enteroviral and other etiologic agents.

**Prashant Ranjan,
Milind Gore, Sriram Selvaraju,
K.P. Kushwaha, D.K. Srivastava,
and Manoj Murhekar**

Author affiliations: Indian Council of Medical Research National Institute of Epidemiology, Chennai, India (P. Ranjan, S. Selvaraju, M. Murhekar); Indian Council of Medical Research National Institute of Virology, Gorakhpur, India (M. Gore); and Baba Raghav Das Medical Collage, Gorakhpur (K.P. Kushwaha, D.K. Srivastava)

DOI: <http://dx.doi.org/10.3201/eid2008.131403>

References

1. Kakkar M, Rogawski ET, Abbas SS, Chaturvedi S, Dhole TN, Hossain SS, et al. Acute encephalitis syndrome surveillance, Kushinagar District, Uttar Pradesh,

India, 2011–2012. *Emerg Infect Dis.* 2013;19:1361–7.

2. Directorate of National Vector Borne Diseases Control Programme. Guidelines for surveillance of acute encephalitis syndrome (with special reference to Japanese encephalitis) [cited 2013 Sep 11]. <http://www.nvb-dcp.gov.in/Doc/AES%20guidelines.pdf>
3. World Health Organization Regional Office for Southeast Asia. Fourth bi-regional meeting on the control of Japanese encephalitis. Report of the meeting Bangkok, Thailand, 7–8 June 2009 [cited 2013 Aug 15]. <http://www.wpro.who.int/immunization/documents/docs/JEBiregionalMeetingJune2009final.pdf>

Address for correspondence: Manoj Murhekar, National Institute of Epidemiology, Indian Council of Medical Research, Chennai-600 070, India; email: mmurhekar@gmail.com

Babesiosis Surveillance, New Jersey, USA, 2006–2011

To the Editor: Since zoonotic babesiosis was first identified in the United States in 1966 (1), its incidence and geographic range have increased (2). Previous studies have demonstrated increases in transfusion-associated cases in recent years (3). In 2011, babesiosis became nationally notifiable as its emergence and the potential for transfusion-associated cases were recognized (2,4). We assessed New Jersey, USA, surveillance data for 2006–2011 to characterize case information (incidence, potential transfusion associations, geographic distribution) in a state where babesiosis is endemic.

In New Jersey, babesiosis case reporting began in 1985. A retrospective study identified an upward trend during 1993–2001; eight of 21 counties reported cases (5). In 2005, the New Jersey Department of Health




Figure. Annual incidence of Japanese encephalitis (JE) and JE-negative acute encephalitis syndrome (AES), Kushinagar District, Uttar Pradesh, India, 2008–2012.

established the Communicable Disease Reporting Surveillance System (CDRSS) to collect detailed information for all reportable communicable diseases from clinicians, hospitals, and laboratories. Babesiosis was classified as confirmed for persons who had clinically compatible illnesses and *Babesia* parasites were detected by blood smear examination and as probable for persons who had clinically compatible illness, including documented anemia or thrombocytopenia, and total antibodies, shown by immunoglobulin or IgG titers of $\geq 1:256$ against *B. microti* by indirect fluorescent test. Cases were considered possibly transfusion associated if patients had documented cellular transfusions with no (or unlikely) other risk factors (e.g., tick bites) reported in CDRSS within 6 months before illness onset. To identify possible transfusion-associated cases, we searched CDRSS text fields for “blood,” “transfusion,” and “receipt of blood donation.” We obtained supportive evidence, when available, for transfusion transmission from medical records or blood center reports. We calculated incidence rates using US Census population data for 2000 (6).

During 2006–2011, a total of 568 babesiosis cases were reported (Figure); 521 (92%) were classified as confirmed and 47 (8%) as probable. In 2006 and 2011, 64 and 166 cases were reported, a 260% increase in reported cases; respective incidence rates were 0.76 and 1.97 cases per 100,000 population. Seven of New Jersey’s 21 counties accounted for 462 (81%) of all reported cases and for 128 (77%) of the 166 cases occurring during 2011. However, all counties reported at least 1 case within the study period, whereas only 8 counties reported cases during 1993–2001 (5) (online Technical Appendix Figure, <http://wwwnc.cdc.gov/EID/article/20/8/13-1591-Techapp1.pdf>). Incidence for 2006–2011 ranged from 0.4 to 39.4 cases per 100,000 population; counties




Figure. Reported confirmed and probable babesiosis cases, New Jersey, USA, 2006–2011. N = 568.

in southern New Jersey had the majority of cases and also reported a high incidence of Lyme disease.

Case-patients’ median age was 66 years (range 1 month–98 years). Two confirmed cases occurred in infants who were believed to have become infected by congenital transmission (7). One infant’s mother was asplenic and had confirmed babesiosis. The other mother was asymptomatic and did not meet case criteria but had reported tick bites.

A total of 371 (65%) case-patients were aged ≥ 60 years of age; 395 (70%) were male. Of the 568 case patients, 401 (71%) had been hospitalized at least once. Of the 303 case-patients for whom information was available 48 (16%) were admitted to an intensive care unit. The all-cause case-fatality rate was 2% (7/357). All 7 persons who died had been hospitalized, 3 of whom had been admitted to intensive care units.

We identified 12 possible transfusion-associated cases (2 in 2006, 1 in 2007, 3 in 2009, 2 in 2010, and 4 in 2011). Two additional transfusion-associated transmissions (1 each in 2006 and 2009) were identified, but these

persons were asymptomatic and not included in this study. Risk factors for possible transfusion-associated cases included surgical procedures with complications requiring transfusions. Median age and case-fatality rate were higher for patients with possible transfusion-associated babesiosis, and these patients were significantly more likely to have acquired infection outside the summer months (online Technical Appendix Table).

Our study has some limitations. Increasing awareness, electronic reporting and testing, and environmental or ecologic factors might have contributed to the upward trend and incidence fluctuations. However, neighboring jurisdictions also observed a similar geographic expansion and overall increase in incidence (8,9). Moreover, New Jersey’s Lyme disease surveillance system shows similar incidence fluctuations for Lyme disease during the study period.

Continued surveillance for detecting babesiosis and investigating possible transfusion-associated cases is needed nationwide (10). Although most cases in our study were reported during summer months, possible

transfusion-associated cases were reported throughout the year, underscoring the need for constant awareness. The 2 cases of probable congenital infection highlight the need to consider *Babesia* infection for newborns who have compatible clinical manifestations, especially if the mother had risk factors for infection.

Prompt identification of babesiosis is essential to prevent disease transmission from infected blood donors to recipients. Although we modified New Jersey surveillance to include transfusion as a risk factor, collaboration with stakeholders (including blood centers) will further facilitate case detection and confirmation and identification of infected donors. Including babesiosis on the list of nationally notifiable diseases will improve national disease reporting and clarify the geographic distribution and incidence of tickborne and possible transfusion-associated cases. With increasing public awareness and screening, public health professionals and stakeholders might consider dedicating public health resources for babesiosis surveillance.

Acknowledgments

We thank Stella Tsai for her assistance and Kris Bisgard and Barbara Herwaldt for their helpful comments.

**Andria Apostolou,
Faye Sorhage,
and Christina Tan**

Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (A. Apostolou); New Jersey Department of Health, Trenton, New Jersey, USA (A. Apostolou, F. Sorhage, C. Tan)

DOI: <http://dx.doi.org/10.3201/eid2008.131591>

References

- Scholtens RG, Braff EH, Healey GA, Gleason N. A case of babesiosis in man in the United States. *Am J Trop Med Hyg.* 1968;17:810–3.
- Centers for Disease Control and Prevention. Babesiosis surveillance—18 states, 2011. *MMWR Morb Mortal Wkly Rep.* 2012;61:505–9.
- Herwaldt BL, Linden JV, Bosserman E, Young C, Olkowska D, Wilson M. Transfusion-associated babesiosis in the United States: a description of cases. *Ann Intern Med.* 2011;155:509–19. <http://dx.doi.org/10.7326/0003-4819-155-8-201110180-00362>
- Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System. National notifiable infectious conditions [cited 2013 Sep 15]. <http://www.cdc.gov/NNDSS/script/conditionsummary.aspx?CondID=24>
- Herwaldt BL, McGovern PC, Gerwel MP, Easton RM, MacGregor RR. Endemic babesiosis in another eastern state, New Jersey. *Emerg Infect Dis.* 2003;9:184–8. <http://dx.doi.org/10.3201/eid0902.020271>
- US Census Bureau. Census 2000 for the state of New Jersey [cited 2013 Sep 15]. <http://www.census.gov/census2000/states/nj.html>
- Sethi S, Alcid D, Kesarwala H, Tolan RW Jr. Probable congenital babesiosis in infant, New Jersey, USA. *Emerg Infect Dis.* 2009;15:788–91. <http://dx.doi.org/10.3201/eid1505.070808>
- Joseph JT, Roy SS, Shams N, Visintainer P, Nadelman RB, Hosur S, et al. Babesiosis in lower Hudson Valley, New York, USA. *Emerg Infect Dis.* 2011;17:843–7. <http://dx.doi.org/10.3201/eid1705.101334>
- New York State Department of Health. Communicable disease annual reports and related information [cited 2014 Feb 15]. <http://www.health.ny.gov/statistics/diseases/communicable/>
- Centers for Disease Control and Prevention. Investigation toolkit: transfusion-transmitted infections (TTI) [cited 2013 Sep 15]. <http://www.cdc.gov/bloodsafety/tools/investigation-toolkit.html>

Address for correspondence: Andria Apostolou, New Jersey Department of Health, Communicable Disease Service, 135 E State St, PO Box 369, Trenton, NJ 08625-0369, USA; email: aapostolou@scimetrica.com

**EMERGING
INFECTIOUS DISEASES**
A Peer-Reviewed Journal Tracking and Analyzing Disease Trends

**Conference
summaries
and other reports
available online**

[http://www.ncc.cdc.gov/eid/articles/
conference-summaries/volume-20](http://www.ncc.cdc.gov/eid/articles/conference-summaries/volume-20)

Antibodies against West Nile and Shuni Viruses in Veterinarians, South Africa


To the Editor: Many arboviruses are zoonotic; humans acquire infection from the bites of arthropod vectors or through exposure to the tissues and body fluids of infected animals. West Nile virus (WNV), a widely endemic zoonotic agent in South Africa, occurs wherever the principal vector (*Culex univittatus* mosquitoes) and avian hosts are present (1). Sero-surveys based on hemagglutination inhibition and neutralization assays conducted during 1950–1970 indicated that 17%–20% of long-term rural residents in the Karoo, 4%–8% in the Highveld, and 1%–3% in the Natal and the Eastern Cape areas had antibodies against WNV (1). Most human infections tend to be sporadic and are characterized by mild febrile illness (2); however, severe disease has been documented (3). WNV has caused severe neurologic disease of horses in South Africa (4), and zoonotic transmission was recorded in a veterinary student who performed a necropsy on an infected horse (5).

Shuni virus (SHUV) (genus *Orthobunyavirus*, family *Bunyaviridae*) was first isolated in Nigeria in 1966 during surveys of livestock, *Culicoides* midges, and mosquitoes, SHUV also once was isolated from a febrile child (6,7). SHUV recently was identified as a previously undetected cause of neurologic disease in horses in southern Africa (8) and is thus of interest in comparison to WNV.

To determine the potential for human infections, we tested veterinarians as a high-risk group for evidence of infection with these 2 viruses. Veterinarians with regular exposure to horses, livestock, or wildlife—and thus to vectors because of an

Babesiosis Surveillance, New Jersey, USA, 2006–2011

Technical Appendix



Technical Appendix Figure. Comparison of rates of babesiosis incidence per 100,000 population, New Jersey, USA. Forty cases were reported during 1993–2001 (1), and 568 cases were reported during 2006–2011 (this study).

Technical Appendix Table. Characteristics of tickborne and potential transfusion-associated babesiosis cases, New Jersey, USA, 2006–2011

Characteristic	Tickborne cases, n = 556	Possible transfusion-associated cases, n = 12	p value
Median age (range)	66 y (1 mo–98 y)	70 y (39–89 y)	0.5408*
Male sex, no. (%)	388 (70)	7 (58)	0.5262†
June–August illness onset, no. (%)‡	467 (84)	2 (17)	0.0001†§
All-cause mortality, no. (%)¶	6 (1.7)	1 (11)	0.1395†

*2-tailed Wilcoxon rank sum test zval: 0.6116, rank sum: 3.7585e+003.

†2-tailed Fisher exact test.

‡Date of reporting to the New Jersey Department of Health was used when illness onset date was not available.

§p<0.05.

¶Included only case-patients for whom information was available. The denominator for tickborne cases was 348; the denominator for transfusion-associated cases was 9.

Reference

1. Herwaldt BL, McGovern PC, Gerwel MP, Easton RM, MacGregor RR. Endemic babesiosis in another eastern state, New Jersey. *Emerg Infect Dis.* 2003;9:184–8. [PubMed](https://pubmed.ncbi.nlm.nih.gov/12500000/)
<http://dx.doi.org/10.3201/eid0902.020271>